Morgan Stanley analyst Terence Flynn maintains $CRISPR Therapeutics (CRSP.US)$ with a sell rating, and maintains the target price at $45.
According to TipRanks data, the analyst has a success rate of 54.8% and a total average return of 8.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $CRISPR Therapeutics (CRSP.US)$'s main analysts recently are as follows:
The company's Q3 update showcased the CTX112 ASH abstract in B-cell malignancies, which presented promising initial efficacy according to the analyst's research note.
The journey for patients undergoing treatment with Casgevy is not brief, yet there are emerging indicators of growing demand. Notably, beyond the first patient infusion, over forty patients have progressed through at least one cell collection phase. Caution is exercised while gauging the time it will take for patient treatment to translate into revenue and subsequently profitability. In terms of upcoming developments, recent data from a lymphoma study showcased a 6-month complete response rate of 44%. Anticipation is high for the comprehensive data reveal to gain a clearer picture of the treatment's potential in the realms of both oncology and autoimmune diseases.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
